NLS Pharmaceutics and Kadimastem merger aims to redefine diabetes treatment with multi-target therapies
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company specialising in therapies for rare and complex central nervous system disorders, is set to merge with Kadimastem ... Read More
NLS Pharmaceutics advances Kadimastem merger with fundraising milestone
NLS Pharmaceutics Ltd., a Swiss biopharmaceutical company focused on therapies for rare central nervous system disorders, and Kadimastem Ltd., an Israeli cell therapy innovator, have ... Read More